



IBA signs contract with China CNNR to install Proteus[®]ONE solution in China

Contract worth between EUR 35 and 40 million

Louvain-la-Neuve, Belgium, 29 May 2018 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with China CNNR to install a Proteus[®]ONE* compact proton therapy solution in China. The contract is fully financed and effective as of today.

The Proteus[®]ONE solution includes Pencil Beam Scanning (PBS) and Cone Beam CT (CBCT) capabilities which makes Proteus[®]ONE the only compact solution ready for adaptive treatment. The contract also includes a long-term maintenance agreement. The typical end-user price for a Proteus[®]ONE solution with a maintenance contract is between EUR 35 and 40 million. The center is expected to start treating patients in 2021 at an undisclosed site in China.

IBA has now sold 52 proton therapy centers worldwide of which 23 are Proteus[®]ONE compact single-room solutions. Including this contract, IBA has signed agreements for five proton therapy rooms in 2018.

The Proteus[®]ONE solution is a unique, truly compact intensity modulated proton therapy (IMPT) system and, alongside its open treatment enclosure and track record of short installation time, it is the solution of choice for an increasing number of hospitals worldwide. The open gantry facilitates patient care and comfort, and improves positioning procedures.

Olivier Legrain, Chief Executive Officer of IBA, commented: "We are delighted that IBA has been selected by China CNNR to deliver a new proton therapy system in China. This confirms IBA's position as a trusted partner for the development and delivery of proton therapy treatment facilities around the world and further strengthens our leading position in China with a market share of more than 60%. IBA is proud to be playing an important role in bringing cutting edge cancer treatment modalities to more patients in China."

Mr. Chen Jiguang, Chairman of China CNNR, added: "China CNNR is pleased to partner with IBA to install the first compact therapy center in China. Our goal is to make proton therapy technology available to more cancer patients in China. IBA is the market leader in the provision of proton therapy and its experience and technological leadership, including the capacity to install its equipment much faster than competition and Pencil Beam Scanning and Cone Beam CT capabilities, make it our partner of choice."

ENDS



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

* *Proteus®ONE is the brand name of Proteus®235.*

About China CNNR

Corresponding to the requirements of state-owned enterprises reform, China CNNR makes efforts to attract private capital to develop a diversified economy, aimed at emerging industries. China CNNR focuses on investment of energy and civil nuclear technology applications, in order to realize five development concepts of innovation, coordination, green development, openness and sharing.

Proton therapy will be a core industry China CNNR strives to develop. China CNNR plans to invest in developing proton therapy centers in the near future to benefit cancer patients in China.

For further information, please contact:

IBA

Soumya Chandramouli

Chief Financial Officer

+32 10 475 890

investorrelations@iba-group.com

Thomas Ralet

Head of Corporate Communication

+32 10 475 890

communication@iba-group.com

Press Release

Inside/regulated information



For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan

+44 (0) 20 3709 5700

IBA@consilium-comms.com